The selected instrumental variables notably diminished the risk of NAFLD and liver fibrosis, indicating that these variables accurately represent the effects of PNPLA3 inhibition. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.